Triple-Negative Breast Cancer
An experimental drug, AMPI-109, shows promise as an immunotherapy that sensitizes triple-negative breast cancer cells, enhancing the effectiveness of the drug.
A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer.
A cocktail of 3 drugs shrank triple-negative breast cancer (TNBC) by killing off cancer cells and halting new tumor growth, a new study conducted in mice and lab-grown human cells has shown.
Vitamin D and androgen receptor-targeted therapy successfully reduced growth and induced death of cancerous cells in a cell culture model of triple-negative breast cancer.
A new drug candidate reduced the growth of tumors in a mouse model of triple negative breast cancer (TNBC) by targeting the RNA, or expression, of a gene only expressed in the diseased cells.
Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.
[Breast Cancer: Basic and Clinical Research] The review examines the standard systemic and future treatment options in metastatic triple-negative breast cancer.
Adrenaline acted on breast cancer cells via the cell surface beta2-adrenoceptor to promote disease growth and invasion, suggesting that beta-blockers might be helpful as adjuvant therapy for patients with aggressive breast cancer.
Adding Carboplatin to Neoadjuvant Therapy for Triple-negative Early Breast Cancer Improves Disease-free SurvivalDecember 09, 2015
Carboplatin added to anthracycline/taxane-based neoadjuvant chemotherapy significantly improved pathological complete response rates in patients with triple-negative breast cancer in two large phase IIb studies: GeparSixto and CALGB 40603. Researchers reported on disease-free survival for GeparSixto after median 35 months of observation at the 2015 San Antonio Breast Cancer Symposium.
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult-to-treat and aggressive form of the disease.
Understanding the Triple Negative Breast Cancer Patient: Tips and Tools for Health Care ProfessionalsOctober 21, 2015
Although treatment options are different and recurrence rates higher for triple negative breast cancer, patients with this subtype of the disease can be hopeful for good treatment outcomes.
A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by targeted treatment.
Enzalutamide may be a viable alternative therapy over cytotoxic chemotherapy for individuals with triple-negative breast cancer, according to a study presented at the 2015 American Society of Clinical Oncology annual meeting.
A new study reveals specific genetic alterations that appear to impact the prognosis and survival rates of African American women.
Preliminary study results indicate that an experimental immune system drug is generally safe and well tolerated in women with metastatic, triple-negative breast cancer.
Researchers have learned more about breast cancer, including identification of a gene that drives the aggressive disease.
Specific methylation patterns revealed in the primary biopsy breast cancer cells of breast cancer DNA methylome can indicate a better or worse prognosis.
Effectiveness of nanoparticle drugs was hindered by tumor microenvironment in triple-negative breast cancerJanuary 29, 2015
Nanoparticle drugs were considered to be a potential silver bullet against cancer, but they have not produced the anticipated improvement in overall survival rates.
Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.
Deleterious mutations were identified in 14.6 percent of patients in a cohort unselected for family history.
Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs currently used to treat rheumatoid arthritis.
Up to a third of triple-negative breast cancer tumors express the androgen receptor. Trails are underway with drugs to inhibit the androgen receptor in much the same way that tamoxifen inhibits the estrogen receptor in ER-positive breast cancers.
Scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast cancer.
The presence of tumor-infiltrating lymphocytes ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer, according to a new study.
An analysis of a large nationwide dataset finds that regardless of their socioeconomic status, triple-negative breast cancer is nearly twice as likely to be diagnosed in black women than in white women.
A gene not previously associated with breast cancer appears to play a pivotal role in the growth and progression of triple-negative breast cancer.
A new study shows that targeting a particular nuclear protein may provide an effective approach for treating triple-negative breast cancer.
A protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells, according to new research.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
- Nonadherence to Posttreatment Imaging Follow-up Common Among Breast Cancer Survivors
- HIIT Improves Cardiorespiratory Fitness in Patients With Resectable NSCLC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|